Company
Headquarters: Lexington, MA, United States
Employees: 122
CEO: Mr. Ronald C. Renaud Jr., MBA
$88,790
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.
| Last Financial Reports Date | June 30, 2024 |
| Revenue TTM | $15.6 M |
| EBITDA | $-28,074,000 |
| Gross Profit TTM | $7.5 M |
| Profit Margin | -292.59% |
| Operating Margin | -328.48% |
| Quarterly Revenue Growth | -71.90% |
Translate Bio, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TBIO wb_incandescent